Aurobindo Pharma Share Price
Sector: Major Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1466.00 -16.70 (-1.13%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1464.3
Today’s High
1486.55
52 Week Low
834.9
52 Week High
1592.55
1468.65 -13.40 (-0.90%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1462.4
Today’s High
1487.05
52 Week Low
834.65
52 Week High
1592
Key Metrics
- Market Cap (In Cr) 86077.71
- Beta 0.91
- Div. Yield (%) 0.3
- P/B 2.91
- TTM P/E 20.09
- Peg Ratio 2.2
- Sector P/E 32.9
- D/E -
- Open Price 1482.7
- Prev Close 1482.7
Aurobindo Pharma Analysis
Price Analysis
-
1 Week-1.81%
-
3 Months8.1%
-
6 Month33.39%
-
YTD36.72%
-
1 Year63.19%
Risk Meter
- 27% Low risk
- 27% Moderate risk
- 27% Balanced Risk
- 27% High risk
- 27% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 6
- Buy
- 13
- 13
- 13
- 12
- Hold
- 5
- 5
- 5
- 3
- Sell
- 2
- 2
- 1
- 1
- Strong Sell
- 2
- 2
- 2
- 2
- Total
- 26
- 26
- 25
- 24
Aurobindo Pharma News
Buy or sell: Ganesh Dongre recommends three stocks for Monday — October 6
2 min read . 06 Oct 2024Stocks to Watch: Mankind Pharma, Suzlon, Adani Ent, Godrej Properties, and more
4 min read . 03 Oct 2024Shares to buy or sell: Ruchit Jain of 5paisa recommends these two stocks today
3 min read . 01 Oct 2024Aurobindo Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 29001.87
- Selling/ General/ Admin Expenses Total
- 3922.94
- Depreciation/ Amortization
- 1521.66
- Other Operating Expenses Total
- 6633.03
- Total Operating Expense
- 24872.39
- Operating Income
- 4129.48
- Net Income Before Taxes
- 4379.99
- Net Income
- 3172.97
- Diluted Normalized EPS
- 56.53
- Period
- 2024
- Total Assets
- 45071.51
- Total Liabilities
- 15228.71
- Total Equity
- 29842.8
- Tangible Book Valueper Share Common Eq
- 439.77
- Period
- 2024
- Cashfrom Operating Activities
- 2434.52
- Cashfrom Investing Activities
- -4255.95
- Cashfrom Financing Activities
- 800.42
- Net Changein Cash
- -1006.84
- Period
- 2023
- Total Revenue
- 24855.38
- Selling/ General/ Admin Expenses Total
- 8189.45
- Depreciation/ Amortization
- 1244.58
- Other Operating Expenses Total
- 518.34
- Total Operating Expense
- 22341.74
- Operating Income
- 2513.64
- Net Income Before Taxes
- 2612.5
- Net Income
- 1927.5
- Diluted Normalized EPS
- 33.03
- Period
- 2023
- Total Assets
- 39889.99
- Total Liabilities
- 13050.14
- Total Equity
- 26839.85
- Tangible Book Valueper Share Common Eq
- 391.13
- Period
- 2023
- Cashfrom Operating Activities
- 2393.16
- Cashfrom Investing Activities
- -3977.75
- Cashfrom Financing Activities
- 1814.41
- Net Changein Cash
- 229.76
- Period
- 2022
- Total Revenue
- 23455.49
- Selling/ General/ Admin Expenses Total
- 7593.01
- Depreciation/ Amortization
- 1126.52
- Other Operating Expenses Total
- 316.95
- Total Operating Expense
- 20399.22
- Operating Income
- 3056.27
- Net Income Before Taxes
- 3372.74
- Net Income
- 2648.15
- Diluted Normalized EPS
- 47.45
- Period
- 2022
- Total Assets
- 33921.72
- Total Liabilities
- 9345.74
- Total Equity
- 24575.98
- Tangible Book Valueper Share Common Eq
- 357.76
- Period
- 2022
- Cashfrom Operating Activities
- 5013.23
- Cashfrom Investing Activities
- -3211.56
- Cashfrom Financing Activities
- -2969.27
- Net Changein Cash
- -1167.4
- Period
- 2021
- Total Revenue
- 24774.62
- Selling/ General/ Admin Expenses Total
- 8108.66
- Depreciation/ Amortization
- 1055.39
- Other Operating Expenses Total
- 317.35
- Total Operating Expense
- 17540.91
- Operating Income
- 7233.71
- Net Income Before Taxes
- 7343.59
- Net Income
- 5334.84
- Diluted Normalized EPS
- 57.91
- Period
- 2021
- Total Assets
- 33853.99
- Total Liabilities
- 11924.12
- Total Equity
- 21929.87
- Tangible Book Valueper Share Common Eq
- 321.03
- Period
- 2021
- Cashfrom Operating Activities
- 3351.33
- Cashfrom Investing Activities
- 598.69
- Cashfrom Financing Activities
- -1364.81
- Net Changein Cash
- 2583.09
- Period
- 2020
- Total Revenue
- 23098.51
- Selling/ General/ Admin Expenses Total
- 7099.39
- Depreciation/ Amortization
- 966.71
- Other Operating Expenses Total
- 364.07
- Total Operating Expense
- 19190
- Operating Income
- 3908.51
- Net Income Before Taxes
- 3743.04
- Net Income
- 2845.14
- Diluted Normalized EPS
- 49.38
- Period
- 2020
- Total Assets
- 28927.74
- Total Liabilities
- 12103.07
- Total Equity
- 16824.67
- Tangible Book Valueper Share Common Eq
- 231.4
- Period
- 2020
- Cashfrom Operating Activities
- 4381.28
- Cashfrom Investing Activities
- -1567.64
- Cashfrom Financing Activities
- -1947.18
- Net Changein Cash
- 871.24
- Period
- 2019
- Total Revenue
- 19563.55
- Selling/ General/ Admin Expenses Total
- 5628.36
- Depreciation/ Amortization
- 667.95
- Other Operating Expenses Total
- 338.59
- Total Operating Expense
- 16348.13
- Operating Income
- 3215.42
- Net Income Before Taxes
- 3091.35
- Net Income
- 2364.73
- Diluted Normalized EPS
- 41.76
- Period
- 2019
- Total Assets
- 26454.36
- Total Liabilities
- 12563.58
- Total Equity
- 13890.78
- Tangible Book Valueper Share Common Eq
- 184.04
- Period
- 2019
- Cashfrom Operating Activities
- 1650.97
- Cashfrom Investing Activities
- -2902.59
- Cashfrom Financing Activities
- 1919.06
- Net Changein Cash
- 665.64
- Period
- 2018
- Total Revenue
- 16499.84
- Selling/ General/ Admin Expenses Total
- 4998.74
- Depreciation/ Amortization
- 557.97
- Other Operating Expenses Total
- 234.48
- Total Operating Expense
- 13252.94
- Operating Income
- 3246.9
- Net Income Before Taxes
- 3241.18
- Net Income
- 2423.17
- Diluted Normalized EPS
- 41.57
- Period
- 2018
- Total Assets
- 21101.04
- Total Liabilities
- 9420.62
- Total Equity
- 11680.42
- Tangible Book Valueper Share Common Eq
- 165.77
- Period
- 2018
- Cashfrom Operating Activities
- 1954.52
- Cashfrom Investing Activities
- -1926.59
- Cashfrom Financing Activities
- 864.15
- Net Changein Cash
- 891.91
- Period
- 2024-06-30
- Total Revenue
- 7567.02
- Selling/ General/ Admin Expenses Total
- 1071.95
- Depreciation/ Amortization
- 404.18
- Other Operating Expenses Total
- 1802.82
- Total Operating Expense
- 6351.63
- Operating Income
- 1215.39
- Net Income Before Taxes
- 1323.89
- Net Income
- 919.22
- Diluted Normalized EPS
- 15.69
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 7580.15
- Selling/ General/ Admin Expenses Total
- 1026.32
- Depreciation/ Amortization
- 354.33
- Other Operating Expenses Total
- 1805.86
- Total Operating Expense
- 6369.5
- Operating Income
- 1210.65
- Net Income Before Taxes
- 1229.9
- Net Income
- 908.75
- Diluted Normalized EPS
- 17.05
- Period
- 2024-03-31
- Total Assets
- 45071.51
- Total Liabilities
- 15228.71
- Total Equity
- 29842.8
- Tangible Book Valueper Share Common Eq
- 439.77
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2434.52
- Cashfrom Investing Activities
- -4255.95
- Cashfrom Financing Activities
- 800.42
- Net Changein Cash
- -1006.84
- Period
- 2023-12-31
- Total Revenue
- 7351.78
- Selling/ General/ Admin Expenses Total
- 989.68
- Depreciation/ Amortization
- 423.27
- Other Operating Expenses Total
- 1610.22
- Total Operating Expense
- 6173.74
- Operating Income
- 1178.04
- Net Income Before Taxes
- 1262.42
- Net Income
- 936.29
- Diluted Normalized EPS
- 16.04
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 7219.42
- Selling/ General/ Admin Expenses Total
- 954.97
- Depreciation/ Amortization
- 417.5
- Other Operating Expenses Total
- 1624.48
- Total Operating Expense
- 6233.69
- Operating Income
- 985.73
- Net Income Before Taxes
- 1075.64
- Net Income
- 757.18
- Diluted Normalized EPS
- 12.83
- Period
- 2023-09-30
- Total Assets
- 43923.59
- Total Liabilities
- 15734.79
- Total Equity
- 28188.8
- Tangible Book Valueper Share Common Eq
- 415.65
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 1500.28
- Cashfrom Investing Activities
- -3061.25
- Cashfrom Financing Activities
- 1292.63
- Net Changein Cash
- -263.38
- Period
- 2023-06-30
- Total Revenue
- 6850.52
- Selling/ General/ Admin Expenses Total
- 951.97
- Depreciation/ Amortization
- 326.56
- Other Operating Expenses Total
- 1592.47
- Total Operating Expense
- 6095.46
- Operating Income
- 755.06
- Net Income Before Taxes
- 812.03
- Net Income
- 570.75
- Diluted Normalized EPS
- 10.58
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 6472.96
- Selling/ General/ Admin Expenses Total
- 851.9
- Depreciation/ Amortization
- 345.57
- Other Operating Expenses Total
- 1727.49
- Total Operating Expense
- 5855.93
- Operating Income
- 617.03
- Net Income Before Taxes
- 730.06
- Net Income
- 506.27
- Diluted Normalized EPS
- 8.64
- Period
- 2023-03-31
- Total Assets
- 39889.99
- Total Liabilities
- 13050.14
- Total Equity
- 26839.85
- Tangible Book Valueper Share Common Eq
- 391.13
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 2393.16
- Cashfrom Investing Activities
- -3977.75
- Cashfrom Financing Activities
- 1814.41
- Net Changein Cash
- 229.76
- Period
- 2022-12-31
- Total Revenue
- 6407.13
- Selling/ General/ Admin Expenses Total
- 921.72
- Depreciation/ Amortization
- 321.4
- Other Operating Expenses Total
- 1623.44
- Total Operating Expense
- 5774.12
- Operating Income
- 633.01
- Net Income Before Taxes
- 680.11
- Net Income
- 491.26
- Diluted Normalized EPS
- 8.38
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Aurobindo Pharma Technical
Moving Average
SMA
- 5 Day1488.24
- 10 Day1476.08
- 20 Day1495.37
- 50 Day1504.79
- 100 Day1387.3
- 300 Day1241.1
Aurobindo Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aurobindo Pharma
- 1466
- -16.7
- -1.13
- 1592.55
- 834.9
- 85892.94
- Pfizer
- 5787.05
- 92.6
- 1.63
- 6452.85
- 3834.4
- 26474.44
- Neuland Laboratories
- 15352.15
- -956.4
- -5.86
- 16501
- 3612.05
- 19696.64
- Astrazeneca Pharma India
- 7623.15
- -8.25
- -0.11
- 8139.85
- 4050.15
- 19057.88
- Unichem Laboratories
- 725.9
- -2.6
- -0.36
- 755.15
- 398.7
- 5110.75
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aurobindo Pharma
- 25.97
- 2.91
- 14.22
- 12.72
- Pfizer
- 48.15
- 7.33
- 18.43
- 24.05
- Neuland Laboratories
- 63.05
- 15.65
- 14.98
- 11.99
- Astrazeneca Pharma India
- 126.67
- 26.74
- 20.1
- 10.27
- Unichem Laboratories
- -
- 2.22
- -2.1
- -3.99
Aurobindo Pharma Shareholding
Shareholding Pattern
*Promoter pledging: 10.56%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 10-Aug-24
- Quarterly Results
- 18-Jul-24
- Buy Back of Shares
- 25-May-24
- Audited Results
- 10-Feb-24
- Quarterly Results & Interim Dividend
- 09-Nov-23
- Quarterly Results & Interim Dividend
- 12-Aug-23
- Quarterly Results
- 27-May-23
- Audited Results
- 09-Feb-23
- Quarterly Results & Interim Dividend
- 12-Nov-22
- Quarterly Results
- 11-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 28-Mar-24
- 22-Feb-24
- POM
- 28-Dec-23
- 24-Nov-23
- POM
- 25-Aug-23
- 28-Jul-23
- AGM
- 23-Mar-23
- 17-Feb-23
- POM
- 02-Aug-22
- 07-Jul-22
- AGM
- 12-Feb-22
- 12-Jan-22
- POM
- 26-Aug-21
- 03-Aug-21
- AGM
- 27-Aug-20
- 03-Aug-20
- AGM
- 29-Aug-19
- 05-Aug-19
- AGM
- 21-Mar-19
- 15-Feb-19
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 07-Feb-24
- 20-Feb-24
- 20-Feb-24
- 1.5
- 02-Nov-23
- 20-Nov-23
- 20-Nov-23
- 3
- 03-Feb-23
- 17-Feb-23
- 17-Feb-23
- 3
- 20-May-22
- 07-Jun-22
- 06-Jun-22
- 4.5
- 09-Feb-22
- 21-Feb-22
- 18-Feb-22
- 1.5
- 08-Nov-21
- 18-Nov-21
- 17-Nov-21
- 1.5
- 12-Aug-21
- 30-Aug-21
- 27-Aug-21
- 1.5
- 10-Feb-21
- 23-Feb-21
- 22-Feb-21
- 1.5
- 11-Nov-20
- 24-Nov-20
- 23-Nov-20
- 1.25
- 12-Aug-20
- -
- 21-Aug-20
- 1.25